Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
LDP Project Team Urges Overhaul of Unpredictable Pricing System: Proposal
A project team of the ruling Liberal Democratic Party (LDP) fostering drug discovery capabilities has hammered out a proposal on a new pharma industry vision, calling for a major overhaul of what it sees as an unpredictable pricing system in…
To read the full story
Related Article
- Lawmakers See No Ultimate Goal in New Pharma Industry Vision
August 6, 2021
- New Pharma Industry Vision to Push Predictability for Investment Recovery: Draft Outline
August 3, 2021
- LDP Project Team on Drug Discovery Capabilities Likely to Meet Aug. 4
July 28, 2021
- LDP Project Team Submits Proposal to Boost Drug Discovery Capabilities
May 24, 2021
- LDP’s Project Team Calls for Audacious Gov’t Investment Targets for Drug Discovery Capabilities
April 30, 2021
- Industry Veteran Prods Appropriate Evaluation for Innovation: LDP Confab
April 16, 2021
- Trade Groups Push Proper Pricing of Innovative Drugs to Restore Attractiveness of Japan: LDP Confab
March 19, 2021
- MHLW Presents Views on “Pharma Industry Vision 2021” to LDP’s Project Team
March 8, 2021
- LDP to Set Up Project Team to Strengthen Pharma Sector, Eyes Proposal in May
February 22, 2021
REGULATORY
- War-Linked Supply Concerns Rise to 43 Cases, Focus Shifts to Solvents, Packaging
April 24, 2026
- JPMA Pushes for “Freeze” on On-Patent Drug Price Cuts at LDP Meeting
April 23, 2026
- MHLW to Exclude High School-Age and Younger from OTC-Like Drug Charge: Official
April 23, 2026
- Japan, Singapore to Share GMP Inspection Results under Cooperation Pact
April 23, 2026
- MHLW Orders Label Revisions for Remicade, Enbrel, Bavencio, and More Drugs
April 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…